Transfusion Medicine Reviews
Volume 21, Issue 1 , Pages 26-36 , January 2007

Transfusion-Transmitted Cytomegalovirus: Lessons From a Murine Model

References 

  1. Pass RF. Cytomegalovirus. In: Fields's virology. Philadelphia: Lippincott-Williams and Wilkins; 2001;p. 2675–2705
  2. Roback JD. Human herpesvirus infections. In: Blood banking and transfusion medicine: Basic principles & practice. Philadelphia: Churchill Livingstone; 2003;p. 465–485
  3. Kreel I, Zaroff LI, Canter JW, et al. A syndrome following total body perfusion. Surg Gynecol Obstet. 1960;111:317–321
  4. Smith D. A syndrome resembling infectious mononucleosis after open-heart surgery. Br Med J. 1964;1:945–948
  5. Alfieri C, Tanner J, Carpentier L, et al. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood. 1996;87:812–817
  6. Dollard SC, Nelson KE, Ness PM, et al. Possible transmission of human herpesvirus-8 by blood transfusion in a historical United States cohort. [see comment] Transfusion. 2005;45:500–503
  7. Hillyer CD, Snydman DR, Berkman EM. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: Transfusion of blood products. Transfusion. 1990;30:659–666
  8. Hillyer CD, Lankford KV, Roback JD, et al. Transfusion of the HIV seropositive patient: Immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5) and HHV-6, 7, and 8. Transfus Med Rev. 1999;13:1–17
  9. Preiksaitis JK. Indications for the use of cytomegalovirus-seronegative blood products. Transfus Med Rev. 1991;5:1–17
  10. Roback JD. CMV and blood transfusions. Rev Med Virol. 2002;12:211–219
  11. Yeager AS, Grumet FC, Hafleigh EB, et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr. 1981;98:281–287
  12. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med. 1986;314:1006–1010
  13. Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 1991;78:246–250
  14. Miller WJ, McCullough J, Balfour HH, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: A randomized trial of blood product screening. Bone Marrow Transplant. 1991;7:227–234
  15. Wilhelm JA, Matter L, Schopfer K. The risk of transmitting cytomegalovirus to patients receiving blood transfusions. J Infect Dis. 1986;154:169–171
  16. Preiksaitis JK, Brown L, McKenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis. 1988;157:523–529
  17. Preiksaitis JK, Desai S, Vaudry W, et al. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study. Transfusion. 1997;37:941–946
  18. Huang ES, Huong SM, Tegtmeier GE, et al. Cytomegalovirus: Genetic variation of viral genomes. Ann N Y Acad Sci. 1980;354:332–346
  19. Adler SP. Transfusion-associated cytomegalovirus infections. Rev Infect Dis. 1983;5:977–993
  20. Stevens DP, Barker LF, Ketcham AS, et al. Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery. JAMA. 1970;211:1341–1344
  21. Adler SP, Baggett J, McVoy M. Transfusion-associated cytomegalovirus infections in seropositive cardiac surgery patients. Lancet. 1985;2:743–747
  22. Winston DJ, Ho WG, Howell CL, et al. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med. 1980;93:671–675
  23. Hersman J, Meyers JD, Thomas ED, et al. The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med. 1982;96:149–152
  24. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153:478–488
  25. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant. Blood. 1995;86:3598–3603
  26. Hillyer CD, Emmens RK, Zago-Novaretti M, et al. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: Filtration versus the use of seronegative donor units. Transfusion. 1994;34:929–934
  27. Bowden R, Sayers M. The risk of transmitting cytomegalovirus infection by fresh frozen plasma. Transfusion. 1990;30:762–763
  28. Diosi P, Moldovan E, Tomescu N. Latent cytomegalovirus infection in blood donors. Br Med J. 1969;4:660–662
  29. Jordan MC. Latent infection and the elusive cytomegalovirus. Rev Infect Dis. 1983;5:205–215
  30. Drew WL, Tegtmeier G, Alter HJ, et al. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients.. Transfusion. 2003;43:309–313
  31. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis. 1990;S701–S710[12 Suppl 7]
  32. Revello MG, Zavattoni M, Sarasini A, et al. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis. 1998;177:1170–1175
  33. Zanghellini F, Boppana SB, Emery VC, et al. Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features. J Infect Dis. 1999;180:702–707
  34. Roback JD, Su L, Newman JL, et al. Transfusion-transmitted cytomegalovirus (CMV) infections in a murine model: Characterization of CMV-infected donor mice. Transfusion. 2006;46:889–895
  35. Reddehase MJ, Podlech J, Grzimek NK. Mouse models of cytomegalovirus latency: Overview. J Clin Virol. 2002;S23–S36(25 Suppl 2)
  36. Rawlinson WD, Farrell HE, Barrell BG. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol. 1996;70:8833–8849
  37. Bruggeman CA, Li F, Stals FS. Pathogenicity: Animal models. Scand J Infect Dis Suppl. 1995;99:43–50
  38. Hanson LK, Slater JS, Karabekian Z, et al. Replication of murine cytomegalovirus in differentiated macrophages as a determinant of viral pathogenesis. J Virol. 1999;73:5970–5980
  39. Pollock JL, Presti RM, Paetzold S, et al. Latent murine cytomegalovirus infection in macrophages. Virology. 1997;227:168–179
  40. Cheung KS, Lang DJ. Transmission and activation of cytomegalovirus with blood transfusion: A mouse model. J Infect Dis. 1977;135:841–845
  41. Jordan CT, Saakadze N, Newman JL, et al. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion. 2004;44:1159–1165
  42. Reiser H, Kuhn J, Doerr HW, et al. Human cytomegalovirus replicates in primary human bone marrow cells. J Gen Virol. 1986;67:2595–2604(Pt 12)
  43. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood. 1999;93:394–398
  44. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci U S A. 1998;95:3937–3942
  45. von Laer D, Meyer-Koenig U, Serr A, et al. Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. Blood. 1995;86:4086–4090
  46. Mendelson M, Monard S, Sissons P, et al. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol. 1996;77:3099–3102(Pt 12)
  47. Sindre H, Tjoonnfjord GE, Rollag H, et al. Human cytomegalovirus suppression of and latency in early hematopoietic progenitor cells. Blood. 1996;88:4526–4533
  48. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119–126
  49. Soderberg-Naucler C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor–alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest. 1997;100:3154–3163
  50. Lathey JL, Spector SA. Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol. 1991;65:6371–6375
  51. Ibanez CE, Schrier R, Ghazal P, et al. Human cytomegalovirus productively infects primary differentiated macrophages. J Virol. 1991;65:6581–6588
  52. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J Virol. 1999;73:4806–4812
  53. Roback JD, Hillyer CD, Drew WL, et al. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion. 2001;41:1249–1257
  54. Roback JD, Bray RA, Hillyer CD. Longitudinal monitoring of WBC subsets in packed RBC units after filtration: implications for transfusion transmission of infections. Transfusion. 2000;40:500–506
  55. Roback JD, Drew WL, Laycock ME, et al. CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion. 2003;43:314–321
  56. Dumont LJ, Luka J, VandenBroeke T, et al. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: A comparison of apheresis and filtration methods. Blood. 2001;97:3640–3647
  57. Payment P, Trudel M. Isolation and identification of viruses. In:  Payment P,  Trudel M editor. Methods and techniques in virology. New York: Marcel Dekker; 1993;p. 33
  58. Jordan MC, Mar VL. Spontaneous activation of latent cytomegalovirus from murine spleen explants. J Clin Invest. 1982;70:762–768
  59. Olding LB, Jensen FC, Oldstone MB. Pathogenesis of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med. 1975;141:561–572
  60. Rowe WP, Hartley JW, Waterman S, et al. Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc Soc Exp Biol Med. 1956;92:418
  61. Presti RM, Pollock JL, Dal Canto AJ, et al. Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med. 1998;188:577–588
  62. Wu BC, Dowling JN, Armstrong JA, et al. Enhancement of mouse cytomegalovirus infection during host-versus-graft reaction. Science. 1975;190:56–58
  63. Dowling JN, Wu BC, Armstrong JA, et al. Enhancement of murine cytomegalovirus infection during graft-vs.-host reaction. J Infect Dis. 1977;135:990–994
  64. Hamilton JD, Seaworth BJ. Transmission of latent cytomegalovirus in a murine kidney tissue transplantation model. Transplantation. 1985;39:290–296
  65. Gilbert GL, Hayes K, Hudson IL, et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet. 1989;1:1228–1231
  66. Verdonck LF, de Graan-Hentzen YC, Dekker AW, et al. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant. 1987;2:73–78
  67. Britt WJ, Alford CA. Cytomegalovirus. In: Fields virology. Philadelphia: Lippincott-Raven; 1996;p. 2493–2523
  68. de Graan-Hentzen YC, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion. 1989;29:757–760
  69. De Witte T, Schattenberg A, Van Dijk BA, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation. 1990;50:964–968
  70. Landaw EM, Kanter M, Petz LD. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection (letter). Blood. 1996;87:4910
  71. Bowden RA, Slichter S, Sayers M. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection (response). Blood. 1996;87:4910–4911
  72. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101:4195–4200
  73. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005;19:181–199
  74. Corash L. Pathogen reduction technology: Methods, status of clinical trials, and future prospects. Curr Hematol Rep. 2003;2:495–502
  75. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423–435
  76. Lin L, Londe H, Janda JM, et al. Photochemical inactivation of pathogenic bacteria in human platelet concentrates. Blood. 1994;83:2698–2706
  77. Hei DJ, Grass J, Lin L, et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion. 1999;39:239–248
  78. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx technology. Semin Hematol. 2001;38:27–33(4 Suppl 11)
  79. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The EuroSPRITE trial. Blood. 2003;101:2426–2433

PII: S0887-7963(06)00058-7

doi: 10.1016/j.tmrv.2006.08.005

Transfusion Medicine Reviews
Volume 21, Issue 1 , Pages 26-36 , January 2007

Article Tools

* Image Usage & Resolution